Gold Silver Reports (GSR) – Strides Shasun Rises On U.S. FDA Nod For HIV Drug — Shares of the Bangalore-based drug maker rose as much as 2.6 percent to Rs 694.35 after it received U.S. drug regulator’s nod for Efavirenz Tablets USP, 600 mg which is used in treatment of HIV-1 for infected adults and adolescents, the company said in an exchange filing.
According to IQVIA data the U.S. market for the drug is approximately $115 million and Strides is only the second generic company to get the approval for the product, the filing added. – Neal Bhai Reports (NBR) INDIA
